CLOVER HEALTH INVESTMENTS CO (CLOV) Stock Analyst Ratings
NASDAQ:CLOV - Nasdaq - US18914F1030 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 76% to CLOV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.17. This target is -5.19% below the current price.
CLOV was analyzed by 11 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about CLOV.
In the previous month the buy percentage consensus was at a similar level.
CLOV was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-17 | Craig-Hallum | Initiate | Buy |
| 2024-10-07 | UBS | Initiate | Neutral |
| 2023-08-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-03-06 | Canaccord Genuity | Maintains | Buy |
| 2023-03-06 | Credit Suisse | Maintains | Underperform |
| 2022-11-16 | Citigroup | Maintains | Neutral |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-08-09 | Credit Suisse | Maintains | Underperform |
| 2022-08-09 | Citigroup | Maintains | Neutral |
| 2022-05-10 | SVB Leerink | Maintains | Market Perform |
| 2022-02-25 | SVB Leerink | Maintains | Market Perform |
| 2022-02-02 | Cowen & Co. | Upgrade | Underperform -> Market Perform |
| 2022-02-02 | Canaccord Genuity | Initiate | Buy |
| 2022-01-19 | SVB Leerink | Initiate | Market Perform |
| 2022-01-07 | Credit Suisse | Downgrade | Neutral -> Underperform |
| 2021-11-15 | Credit Suisse | Maintains | Neutral |
| 2021-09-10 | Cowen & Co. | Initiate | Underperform |
| 2021-07-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-06-10 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-05-19 | Credit Suisse | Maintains | Neutral |
| 2021-05-17 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-03-09 | Credit Suisse | Initiate | Neutral |